1
Shawn D Britt, Kevin M Cottrell, Robert B Perni, Janos Pitlik: Inhibitors of serine proteases, particularly HCV NS3-NS4A protease. Vertex Pharmaceuticals Incorporated, Michael C Badia, Vertex Pharmaceuticals Incorporated, September 19, 2006: US07109172 (24 worldwide citation)

The present invention relates to compounds of formula I or formula Ia or pharmaceutically acceptable salts thereof, that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3–NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus a ...


2
Robert B Perni, John J Court, Shawn D Britt, Janos Pitlik, John H van Drie: Inhibitors of serine proteases, particularly HCV NS3-NS4A protease. Vertex Pharmaceuticals Incorporated, Ropes & Gray, James F Haley Jr, Michele A Kercher, May 27, 2008: US07378422 (22 worldwide citation)

The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to ...


3

4
Robert B Perni, John J Court, Shawn D Britt, Janos Pitlik, John H van Drie: Inhibitors of serine proteases, particularly HCV NS3-NS4A protease. Vertex Pharmaceuticals Incorporated, Ropes & Gray, James F Haley Jr, June 29, 2010: US07745444 (3 worldwide citation)

The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to ...


5
Robert B Perni, John J Court, Shawn D Britt, Janos Pitlik, John H van Drie: Inhibitors of serine proteases, particularly HCV NS3-NS4A protease. Vertex Pharmaceuticals Incorporated, Ropes & Gray, James F Haley Jr, Yang Xu, July 10, 2012: US08217048 (1 worldwide citation)

The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to ...


6

7
Shawn D Britt, Kevin M Cottrell, Robert B Perni, Janos Pitlik: Inhibitors of serine proteases, particularly HCV NS3-NS4A protease. Vertex Pharmaceuticals Incorporated, Lisa A Dixon, Susan C Kelly, April 8, 2014: US08691758

The present invention relates to compounds of formula I or formula Ia or pharmaceutically acceptable salts thereof, that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus a ...


8
Govinda R Bhisetti, Jeffrey O Saunders, Mark A Murcko, Christopher A Lepre, Shawn D Britt, Jon H Come, David D Deininger, Tianshang Wang: Inhibitors of bace. Vertex Pharmaceuticals Incorporated, May 22, 2003: US20030095958-A1

The present invention relates to inhibitors of aspartic proteinases, particularly, BACE. The present invention also relates to compositions thereof and methods therewith for inhibiting BACE activity in a mammal, and for treating Alzheimer's Disease and other BACE-mediated diseases.


9

10
Robert B Perni, John J Court, Shawn D Britt, Janos Pitlik, John H van Drie: Inhibitors of serine proteases, particularly HCV NS3-NS4A protease. Vertex Pharmaceuticals Incorporated, Ropes & Gray, December 18, 2008: US20080311079-A1

The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to ...